An antibiotic composition containing a wasp extract as an active ingredient, and more particularly, a pharmaceutical composition and a health functional food for preventing, ameliorating or treating diabetes by α-amylase inhibition and α-glucosidase inhibition, which contain a wasp extract as an active ingredient. The wasp extract exhibits strong antidiabetic activity by effectively inhibiting amylase, has no human erythrocyte hemolytic activity, has excellent heat stability, and the activity thereof is not lost even under an acidic condition of pH 2 and in plasma. The wasp extract of the present disclosure may be processed into various forms such as extracts, powders, pills or tablets, which can be taken at all times.

An antibiotic composition containing a wasp extract as an active ingredient, and more particularly, a pharmaceutical composition and a health functional food for preventing, ameliorating or treating diabetes by α-amylase inhibition and α-glucosidase inhibition, which contain a wasp extract as an active ingredient. The wasp extract exhibits strong antidiabetic activity by effectively inhibiting amylase, has no human erythrocyte hemolytic activity, has excellent heat stability, and the activity thereof is not lost even under an acidic condition of pH 2 and in plasma. The wasp extract of the present disclosure may be processed into various forms such as extracts, powders, pills or tablets, which can be taken at all times.

The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.

The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.

A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

A food composition and pharmaceutical composition with strains of lactic acid bacteria for modulating blood glucose are provided, comprising an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including a GL-104 strain of Lactobacillus reuteri (CCTCC NO: M209138), an AP-32 strain of Lactobacillus salivarius subsp. salicinius (CCTCC NO: M2011127), a TYCA06 strain of Lactobacillus acidophilus (CGMCC No: 15210), and an MH-68 strain of Lactobacillus johnsonii (CCTCC NO: M2011128), or a combination thereof.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure.

There are provided compounds of Formula I: ##STR00001##
various compositions thereof and methods for their use in the inhibition of α-amylase.

There are provided compounds of Formula I: ##STR00001##
various compositions thereof and methods for their use in the inhibition of α-amylase.